CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
The purpose of this clinical investigation is to evaluate the safety and effects of CCCR-modified NK92(CCCR-NK92)infusions in previously treated advanced non-small cell lung carcinoma(NSCLC).
Non-small Cell Lung Cancer
BIOLOGICAL: CCCR-NK92 cells
Number of participants with adverse events evaluated with CTCAE,version 4.0, Safety evaluation, 3 months|Objective Response Rate, Non-small cell lung carcinoma to CCCR-NK92 cell infusions, up to one year
Disease Control Rate, up to one year|Progression-free Survival, up to one year|Overall Survival, up to one year
The purpose of this clinical investigation is to evaluate the safety and effects of CCCR-modified NK92(CCCR-NK92)infusions in previously treated advanced non-small cell lung carcinoma(NSCLC).